Casdin Capital, LLC bought $5.2M of Standard Biotools (LAB)

Executed Feb 28 2025, disclosed Mar 4 2025, 4 days later.

Value, as filed

$5.2M

4,820,959 sh × $1.07

Executed

Feb 28 2025

the trade date, as filed

Disclosed

Mar 4 2025

4 days after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

+9.0%

+6.5% from execution

Over the 21 trading sessions from the disclosed entry session (Mar 4 2025), the stock returned +9.0% (delay-adjusted); from the execution session (Feb 28 2025), +6.5%. Derived: entry at the session's open, exit at the close 20 sessions later.

The filer

CL Casdin Capital, LLC Director profile →

Casdin Capital, LLC (Director) filed 2 Form 4 reports as a reporting entity in the trailing twelve months (2 purchases, 0 sales), most often in GeneDx Holdings Corp. (WGS). Across 2 priced purchase filings, the average 21-session return was +36.2% from execution and +32.5% from disclosure (delay-adjusted; derived). The largest single filing was $21.5M of WGS (500,000 sh across 3 lots, as filed), executed May 18.

The name

LAB LAB LAB · 10 filings in 24 months ticker → Insider filings, newest first→ View the original filing at www.sec.gov→